Our Vision & Experience

Millions of people suffer every year from inadequate outcomes and severe side effects of prescription medications that were meant to help them. Our discoveries have the potential to change and improve lives.

Founders, Dr. Brian D. Athey and Dr. James S. Burns
Phenomics Health logo
University of Michigan logo

For decades, researchers have pursued coding-gene pharmacogenomic testing as a way of improving medication selection and reducing medication side effects. Despite advances, the results have been limited in their ability to predict patient outcomes, interpret drug-drug interactions, and avoid potential adverse reactions.

The Breakthrough

A University of Michigan team, led by Dr. Brian D. Athey, developed a breakthrough technology for determining how individual genes are impacted by specific drugs, when evaluated in a combination with external environmental factors and patient traits, such as network biology, ethnicity, environment, sociological factors, and recorded health history. 

The result is a highly predictive profile of a patient’s unique drug response or phenotype. Athey and biotechnology entrepreneur Dr. James S. Burns evaluated the potential applications of advanced pharmacogenomics and created a plan to move the technology forward. Phenomics Health Inc. (PHI) was launched in 2018 and PHI’s proprietary Precision Phenome Platform™ (P3) was introduced.


Dedicated to commercializing novel pharmacogenomic and precision medicine products and services across therapeutic areas associated with chronic pain, mental illness, stress, and cardiovascular disease.


Phenomics Health provides contract-based and collaborative research services to test mechanisms and pathways for new and repurposed drugs, including CNS, cardiovascular disease, cancer, GI, and immune system disorders.


Patented pharmacogenomic technology, enabled by Artificial Intelligence (AI) and Machine Learning, fuels the precision of Phenomics Health technological breakthroughs.

Phenomics Health’s technology is based on University of Michigan inventions, licensed exclusively to Phenomics Health. The company has two issued and multiple pending patents.

Proprietary Intellectual Property and multiple products in development
Proprietary Phenome Analytics Support Platform
Multiple publications supporting its core technology and specific applications
Multiple pending collaborations and partnerships with key U.S. and international institutions
International and external informatics with hosted secure cloud server support
Access to multiple proprietary informatics and multiple technologies and data sets

Our Team

Brian Athey

Brian D. Athey

Founding Partner
Chief Science & Tech Officer

Omenn headshot

Gilbert S. Omenn

Director and Chair,
Scientific Advisory Board (SAB)

Alex Ade headshot

Alex Ade​

Principal Software Architect

michaela gallucci

Michaela Gallucci

Software Engineer

Gerry Higgins

Gerry Higgins

Senior PGx Scientist

Wenbing Chen

Wenbing Chen

Laboratory Director

Madison Censoni

Madison Censoni

Associate Lab Manager

Guy Giordano

Guy Giordano


Rajvi Patel

Rajvi Patel

Laboratory Technologist

Cassandra Snyder

Laboratory Technologist


Dylan Kakos

Medical Science Liaison

Eric Bell

Eric Bell

Director of Sales

Our Scientific Advisors

Nicholas J. Schork, Ph.D.

Nicholas J. Schork, Ph.D.

Distinguished Professor and Director of Quantitative Medicine at The Translational Genomics Research Institute (TGen)

Veera Baladandayuthupani Ph.D.

Veera Baladandayuthupani, Ph.D.

Professor of Biostatistics, University of Michigan

Ryan B. Morrison

Ryan B. Morrison, B.Sc.

Director of Operations, Protypia Laboratory Innovator of Quantitative PK/PD Assays, Specializing in High Throughput Drug Metabolism Assays

Join the conversation.

Keep up with our latest news and innovation by following us on LinkedIn.